RecruitingPhase 1NCT07160738

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, TWO-COHORT, TWO-PERIOD, FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSES OF ITRACONAZOLE AND PROBENECID ON THE PHARMACOKINETICS OF SINGLE DOSE PF-07220060 ADMINISTERED UNDER THE FED CONDITION TO HEALTHY PARTICIPANTS

Sponsor

Pfizer

Enrollment

28 participants

Start Date

Sep 22, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy Adults

Summary

The purpose of the study is to see and learn the effect of multiple doses of a strong CYP3A4 inhibitor and a potent UGT2B7 inhibitor on the PK of PF-07220060.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This is a drug-interaction study in healthy volunteers testing how two common medications — itraconazole (an antifungal) and probenecid (a gout treatment) — affect how the body processes an experimental drug called PF-07220060. Understanding these interactions helps researchers set safe dosing guidelines. **You may be eligible if...** - You are a healthy adult with no significant medical conditions - Your BMI is between 17.5 and 30.5 kg/m² and you weigh more than 50 kg **You may NOT be eligible if...** - You have a history of blood disorders, kidney stones (uric acid type), peptic ulcers, or gout (for the probenecid part of the study) - You are currently taking medications that significantly interact with liver enzymes (CYP3A4 or UGT2B7 inhibitors/inducers) - You are taking methotrexate, certain painkillers (NSAIDs like naproxen), or certain antibiotics Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.